ORF Genetics—a molecular farming company pioneering the production of growth factors in barley—has raised €5m ($5.9m) to ...

A phase II study of erlotinib plus capecitabine (XEL) as first-line treatment for elderly patients (pts) with advanced adenocarcinoma of lung (ML 22206 study). Background: Detecting epidermal growth ...

All products featured on Vogue are independently selected by our editors. However, we may receive compensation from retailers and/or from purchases of products through these links. It almost feels ...